Trade PTGX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Protagonist Therapeutics, Inc. (PTGX) is trading at US$134.38, down 0.36% today as of Nov 12, 16:00 EST. The company has a market capitalisation of US$9.99B. Over the past 52 weeks, PTGX has traded between US$77.00 and US$160.81. On Syfe you can trade PTGX with $0 commission and add it to your watchlist.
| Previous close | US$134.86 |
|---|---|
| Market cap | US$9.99B |
| P/E ratio | 209.61 |
| 52-week range | US$77.00 – US$160.81 |
| Volume | 542.88K |
| Exchange | US |
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Year: 2016
UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target
Oct 12, 11:38 AM · MT Newswires
Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC Filing
Sep 11, 7:23 AM · MT Newswires
Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says
Aug 31, 6:53 PM · MT Newswires
Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept
Aug 31, 6:40 PM · MT Newswires
Protagonist Therapeutics, Inc. (PTGX) stock is trading at US$134.38, -0.36% from the previous close of US$134.86.
The market cap for Protagonist Therapeutics, Inc. (PTGX) stock is approximately US$9.99B.
The price-to-earnings ratio for Protagonist Therapeutics, Inc. (PTGX) is 209.61, based on the latest reported earnings.
The 52-week high for Protagonist Therapeutics, Inc. (PTGX) stock is US$160.81.
The 52-week low for Protagonist Therapeutics, Inc. (PTGX) stock is US$77.00.
Protagonist Therapeutics, Inc. (PTGX) does not currently pay a dividend.
Stay on top of PTGX
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
